Antineoplastic Effects of α-Santalol on Estrogen Receptor-Positive and Estrogen Receptor-Negative Breast Cancer Cells through Cell Cycle Arrest at G2/M Phase and Induction of Apoptosis

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Santha, Sreevidya ^a   Bommareddy, Ajay ^b   Rule, Brittny ^b   Guillermo, Ruth ^a   Kaushik, Radhey S ^a   Young, Alan ^a   Dwivedi, Chandradhar ^a  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

^b WILKES UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 8; CASPASE 9; CELL CYCLE PROTEIN; CELL DIVISION CYCLE 25B; CELL DIVISION CYCLE 25C; CHECKPOINT KINASE 1; CYCLIN DEPENDENT KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P21; PROTEIN P53; SANTALOL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN MCF 7; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; G2 PHASE; HUMANS; IN SITU NICK-END LABELING; RECEPTORS, ESTROGEN; SESQUITERPENES;

EID: 84874316347     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056982     Document Type: Article

References (45)

1. Zhang X, Dwivedi C, (2011) Skin cancer chemoprevention by α-santalol. Front Biosci (Schol Ed) 3: 777-787.
2. Burdock GA, Carabin IG, (2008) Safety assessment of sandalwood oil (Santalum album L.) Food Chem Toxicol. 46: 421-432.
3. Dwivedi C, Guan X, Harmsen WL, Voss AL, Goetz-Parten DE, et al. (2003) Chemopreventive effects of α-santalol on skin tumor development in CD-1 and SENCAR mice. Cancer Epidemiol Biomarkers Prev 12: 151-156.
4. Dwivedi C, Valluri HB, Guan X, Agarwal R, (2006) Chemopreventive effects of α-santalol on ultraviolet B radiation-induced skin tumor development in SKH-1 hairless mice. Carcinogenesis 27: 1917-1922.
5. Kaur M, Agarwal C, Singh RP, Dwivedi C, Agarwal R, (2005) Skin cancer chemopreventive agent, α-santalol, induces apoptotic death of human epidermoid carcinoma A431 cells via caspase activation together with dissipation of mitochondrial membrane potential and cytochrome c release. Carcinogenesis 26: 369-380.
6. Bommareddy A, Rule B, VanWert AL, Santha S, Dwivedi C, (2012) α-Santalol, a derivative of sandalwood oil, induces apoptosis in human prostate cancer cells by causing caspase-3 activation. Phytomedicine 19: 804-811.
7. Rochefort H, Glondu M, Sahla ME, Platet N, Garcia M, (2003) How to target estrogen receptor-negative breast cancer?. Endocr Relat Cancer 10: 261-266.
8. Parl FF, Schmidt BP, Dupont WD, Wagner RK, (1984) Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer 54: 2237-2242.
9. Crowe JP Jr, Gordon NH, Hubay CA, Shenk RR, Zollinger RM, et al. (1991) Estrogen receptor determination and long term survival of patients with carcinoma of the breast. Surg Gynecol Obstet 173: 273-278.
10. Anderson WF, Chu KC, Chatterjee N, Brawley O, Brinton LA, (2001) Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. J Clin Oncol 9: 18-27.
11. Rivera E, Gomez H (2010) Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Res (Suppl 2): S2.
12. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN, (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608: 1-22.
13. Swerdlow AJ, Jones ME, (2005) Tamoxifen Treatment for Breast Cancer and Risk of Endometrial Cancer: A Case - Control Study. J Natl Cancer Inst 97: 375-384.
14. Howes MJ, Simmonds MS, Kite GC, (2004) Evaluation of the quality of sandalwood essential oils by gas chromatography-mass spectrometry. J Chromatogr A 1028: 307-312.
15. Zhang X, Chen W, Guillermo R, Chandrasekher G, Kaushik RS, et al. (2010) Alpha-santalol, a chemopreventive agent against skin cancer, causes G2/M cell cycle arrest in both p53-mutated human epidermoid carcinoma A431 cells and p53 wild-type human melanoma UACC-62 cells. BMC Res Notes 3: 220.
16. Collins JA, Schandi CA, Young KK, Vesely J, Willingham MC, (1997) Major DNA Fragmentation Is a Late Event in Apoptosis. J Histochem Cytochem 45: 923-934.
17. Deep G, Singh RP, Agarwal C, Kroll DJ, Agarwal R, (2006) Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene 25: 1053-1069.
18. Park MT, Lee S, (2003) Cell Cycle and Cancer. J Biochem Mol Biol 36: 60-65.
19. Mueller PR, Coleman TR, Kumagai A, Dunphy WG, (1995) Myt1: a membrane-associated inhibitory kinase that phosphorylates cdc2 on both Threonine-14 and Tyrosine-15. Science 270: 86-90.
20. Gautier J, Solomon MJ, Booher RN, Bazan JF, Kirschner MW, (1991) Cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2. Cell 67: 197-211.
21. Singh SV, Herman-Antosiewicz A, Singh AV, Lew KL, Srivastava SK, et al. (2004) Sulforaphane-induced G2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C. J Biol Chem 279: 25813-25822.
22. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
23. Newman DJ, Cragg GM, Snader KM, (2003) Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 66: 1022-1037.
24. Ferreira CG, Epping M, Kruyt FA, Giaccone G, (2002) Apoptosis: Target of Cancer Therapy. Clin. Cancer Res 8: 2024-2034.
25. Shapiro GI, Harper JW, (1999) Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest 104: 1645-1653.
26. Sun SY, Hail N Jr, Lotan R, (2004) Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst 96: 662-672.
27. Elmore S, (2007) Apoptosis: A Review of Programmed Cell Death. Toxicol Pathol 35: 495-516.
28. Slee EA, Adrain C, Martin SJ, (2001) Executioner caspase-3,-6, and-7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem 276: 7320-7326.
29. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, et al. (1998) A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391: 43-50.
30. Wolf BB, Schuler M, Echeverri F, Green DR, (1999) Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/Inhibitor of caspase-activated Dnase inactivation. J Biol Chem 274: 30651-30656.
31. Liu X, Zou H, Widlak P, Garrard W, Wang X, (1999) Activation of the apoptotic endonuclease DFF40 (caspase-activated DNase or nuclease). Oligomerization and direct interaction with histone H1. J Biol Chem 274: 13836-13840.
32. Nizamutdinova IT, Lee GW, Son KH, Jeon SJ, Kang SS, et al. (2008) Tanshione I effectively induces apoptosis in estrogen receptor-positive (MCF- 7) and estrogen receptor-negative (MDA-MB-231) breast cancer cells. Int J Oncol 33: 485-491.
33. Yang HL, Chen CS, Chang WH, Lu FJ, Lai YC, et al. (2006) Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by Antrodia camphorata. Cancer Lett 23: 215-227.
34. Chen JS, Konopleva M, Andreeff M, Multani AS, Pathak S, et al. (2004) Drug-resistant breast carcinoma (MCF-7) cells are paradoxically sensitive to apoptosis. J Cell Physiol 200: 223-234.
35. Janicke RU, Sprengart ML, Wati MR, Porter AG, (1998) Caspase- 3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273: 9357-9360.
36. Oberhammer F, Wilson JW, Dive C, Morris ID, Hickman JA, et al. (1993) Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J 12: 3679-3684.
37. Sakahira H, Enari M, Nagata S, (1998) Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 391: 96-99.
38. Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, et al. (1998) Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 273: 33533-33539.
39. Michalides RJ, (1999) Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer. J Clin Pathol 52: 555-568.
40. Wolf F, Wandke C, Isenberg N, Geley S, (2006) Dose-dependent effects of stable cyclin B1 on progression through mitosis in human cells. EMBO J 25: 2802-2813.
41. Whitfield WG, Gonzalez C, Maldonado-Codina G, Glover DM, (1990) The A- and B-type cyclins of Drosophila are accumulated and destroyed in temporally distinct events that define separable phases of the G2-M transition. EMBO J 9: 2563-2572.
42. Nilsson I, Hoffmann I, (2000) Cell cycle regulation by the Cdc25 phosphatase family. Prog Cell Cycle Res 4: 107-114.
43. Yarden RI, Pardo-Reoyo S, Sgagias M, Cowan KH, Brody LC, (2002) BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 30: 285-289.
44. Lin S, Rai R, Li K, Xu Z, Elledge SJ, (2005) BRIT1MCPH1 is a DNA damage responsive protein that regulates the Brca1-Chk1 pathway, implicating checkpoint dysfunction in microcephaly. PNAS 102: 15105-15109.
45. Megyesi J, Udvarhelyi N, Safirstein RL, Price PM, (1996) The p53-independent activation of transcription of p21 WAF1/CIP1/SDI1 after acute renal failure. Am J Physiol 1: 1211-1216.